Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcased over 1,000 innovative products from more than 300 leading global pharmaceutical and medical device companies, covering the latest achievements in high-end medical devices, innovative drugs, and AI applications [1] - The exhibition featured ten major exhibition areas, including medical imaging, emergency rescue, rehabilitation, and artificial intelligence, creating a comprehensive platform for display, communication, and collaboration within the pharmaceutical and medical device industry [1] - The event was organized by the China Medical Equipment Association, the National High-Performance Medical Device Innovation Center, and the Shenzhen Medical Device Industry Association [1] Group 2 - The exhibition highlighted advancements in future medical technologies, such as robotic surgery, advanced imaging equipment, brain-machine interfaces, and AI-assisted rehabilitation tools, demonstrating the potential of these innovations [2] - Notable products included the multi-port and single-port laparoscopic surgical robots from Qingfeng Medical, and an AI-based drug-device research public service platform from Particle Technology, which significantly reduces traditional research and development timelines [2] - Major companies like Mindray and Siemens showcased their cutting-edge medical equipment, emphasizing the clinical applications and enhanced imaging capabilities of their products [2] Group 3 - The pharmaceutical and medical device industry in Shenzhen has seen continuous growth, with an industry output value reaching 157.6 billion yuan in 2024, including over 102.8 billion yuan from medical devices, maintaining the top position in the country for ten consecutive years [3] - Shenzhen has nurtured 35 listed companies and 143 enterprises with an output value exceeding 100 million yuan in the pharmaceutical and medical device sector, with leading firms such as Mindray and Xintai emerging in various market segments [3] - The exhibition served as a platform for the release of significant collaborations and innovations, including a $1.64 billion strategic partnership between Pruijin and Kite for in vivo CAR-T therapies, showcasing the global push for cell therapy technologies [3]

Core Viewpoint - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition aims to create an industry exchange platform, focusing on the theme of "Innovative Drugs and Devices, Collaborative Win-Win" to showcase cutting-edge achievements in the pharmaceutical and medical device industries and promote cooperation between Shenzhen and Hong Kong [1] Group 1: Exhibition Overview - The exhibition will take place in Hong Kong on December 11 and in Shenzhen from December 18 to 20, featuring a dual-city model [1] - The Hong Kong segment will focus on international clinical trials, technology and product exports, cell and gene therapy, AI in medical devices, and brain science [1] - The Shenzhen segment will cover the entire pharmaceutical and medical device supply chain, showcasing high-performance medical devices and innovative pharmaceuticals, including biomanufacturing, AI+healthcare, aesthetic devices, and home health [1] Group 2: Participation and Forums - The exhibition will feature over 300 participating companies and institutions, including global leaders like Siemens Healthineers, Medtronic, and Abbott, as well as domestic pioneers [2] - More than 20 high-level sub-forums will be held, addressing key topics such as policy interpretation, cutting-edge technology, clinical practice, market trends, and investment financing [2] - Notable experts and over 2,500 industry leaders will attend the opening ceremony and forums to share insights [2] Group 3: Highlights and Achievements - The exhibition will showcase five major highlights: high standards, broad fields, complete supply chains, new achievements, and a comprehensive ecosystem [3] - Significant technological advancements in Shenzhen's pharmaceutical and medical device sectors will be announced during the opening ceremony [3] - Shenzhen's medical device industry has been integrated into the "20+8" key industrial clusters, with a projected growth in output value from 128 billion to 157.6 billion yuan from 2020 to 2024, maintaining an annual growth rate of 5.3% [3]

Core Viewpoint - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition will take place in two phases, with the Hong Kong station starting on December 11 and the main exhibition in Shenzhen from December 18 to 20, showcasing advancements in the medical device and pharmaceutical industries [1][2]. Group 1: Exhibition Overview - The exhibition adopts a "one exhibition, two cities" model, focusing on the latest achievements from innovation to industrial transformation, and aims to create a platform for industry exchange, resource integration, and trade [2][3]. - The Hong Kong station will emphasize international clinical trials, technology and product exports, and new fields such as AI in medical devices and brain science, while the Shenzhen station will cover the entire pharmaceutical and medical device supply chain [2][3]. Group 2: Industry Development - Shenzhen's pharmaceutical and medical device output is projected to grow from 128 billion yuan in 2020 to 157.6 billion yuan by 2024, with an annual growth rate of 5.3%, maintaining its position as the national leader in medical device output [3]. - The city plans to establish a development framework consisting of "one corridor, two zones, and three bases" to enhance its biopharmaceutical and medical device industries [3]. Group 3: Regional Focus - Pingshan District, as a national biopharmaceutical industry base, has established 13 specialized parks covering over 2.79 million square meters, with a compound annual growth rate of 39.8% in enterprise numbers [4]. - The Guangming District has attracted over 900 medical device companies and is focusing on building a comprehensive ecosystem for biomanufacturing and innovative medical devices [5][6]. Group 4: Exhibition Highlights - The exhibition will feature over 300 participating companies, including international giants like Siemens and Medtronic, and will host more than 20 sub-forums covering key topics such as policy interpretation and cutting-edge technologies [7][8]. - This year's exhibition will continue to emphasize the dual focus on pharmaceuticals and medical devices, showcasing a wide range of innovations and establishing a complete industry chain from research to application [7][8].

Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition is fully prepared, featuring over 300 exhibitors from various countries, including multinational companies like Siemens Healthineers and Medtronic, as well as domestic leaders such as China Resources, Mindray, and Jingfeng Technology [1][2] - The exhibition will follow the theme "Innovative Drugs and Devices, Collaborative Win-Win," highlighting five key features: high specifications, broad fields, complete chains, new achievements, and a comprehensive ecosystem [1] - The event will include over 20 sub-forums covering six key topics, promoting deep exchanges among industry, academia, research, medical, financial, and governmental sectors [1] Group 2 - The exhibition will adopt a "One Exhibition, Two Cities" model, showcasing the latest achievements from source innovation to industrial transformation, and facilitating industry exchanges, resource matching, and trade transactions [2] - The Hong Kong segment will start on December 11, focusing on international clinical trials, technology and product exports, cell and gene therapy, AI in medical devices, and brain science, emphasizing the role of Shenzhen-Hong Kong cooperation in advancing the pharmaceutical and medical device industries [2] - The main Shenzhen exhibition will take place from December 18 to 20 at the Shenzhen Convention and Exhibition Center, covering the entire chain of pharmaceuticals and medical devices, and showcasing emerging fields such as biomanufacturing, AI+medical devices, aesthetic medical devices, and home health [2]

Core Viewpoint - Shenzhen is positioning itself as a leading hub for the biopharmaceutical and high-end medical device industries, with significant growth in production value and exports projected through 2024 [1][2]. Group 1: Industry Growth and Development - From 2020 to 2024, the production value of Shenzhen's biopharmaceutical and medical device sectors is expected to increase from 128 billion to 157.6 billion yuan, with an average annual growth rate of 5.3% [1][2]. - Medical device production value is projected to rise from 83.1 billion to 102.8 billion yuan, maintaining the top position in the country [1][2]. - In 2024, the total export value of pharmaceuticals and medical devices is anticipated to reach 41.38 billion yuan, with medical device exports alone accounting for 29.85 billion yuan, also ranking first nationally [1][2]. Group 2: Strategic Initiatives - Shenzhen plans to establish an "industrial development pattern" consisting of "one corridor, two zones, and three bases" to enhance its biopharmaceutical sector [2]. - The "4+4+N" development strategy will focus on four emerging tracks, including cell and gene therapy, and will promote key projects in research and development and international expansion [2]. Group 3: Infrastructure and Ecosystem - The Pingshan District, as a national-level biopharmaceutical industrial base, has developed 13 specialized parks covering over 2.79 million square meters, with an annual compound growth rate of enterprises at 39.8% [2]. - The Guangming District hosts over 900 medical device companies and is developing a comprehensive ecosystem that includes technological innovation, clinical research, and policy support [3]. Group 4: Upcoming Events and Innovations - The Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition will take place from December 18 to 20, showcasing advancements in biomanufacturing, AI in pharmaceuticals, and other emerging fields [4][5]. - The exhibition will feature over 300 participating companies, including major international and domestic players, and will highlight new drug developments and clinical trials [5][6].